Literature DB >> 16625579

Directly observed therapy for treating tuberculosis.

J Volmink1, P Garner.   

Abstract

BACKGROUND: People with tuberculosis require treatment for at least six months. As many patients do not complete their treatment, policies have been introduced to encourage adherence to treatment regimens. One such policy is directly observed therapy, which involves people directly observing patients taking their antituberculous drugs.
OBJECTIVES: To compare directly observed therapy (DOT) with self administration of treatment in people requiring treatment for clinically active tuberculosis or prevention of active disease. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group Specialized Register (November 2005), CENTRAL (The Cochrane Library 2005, Issue 4), MEDLINE (1966 to November 2005), EMBASE (1974 to November 2005), LILACS (1982 to November 2005), and reference lists of articles. We also contacted researchers and organizations working in the field. SELECTION CRITERIA: Randomized and quasi-randomized controlled trials comparing a health worker, family member, or community volunteer routinely observing people taking antituberculous drugs compared with routine self administration of treatment at home. We include patients requiring treatment for clinically active tuberculosis or medication for preventing active disease. DATA COLLECTION AND ANALYSIS: Both authors independently assessed trial methodological quality and extracted data. Data were analysed using relative risks (RR) with 95% confidence intervals (CI) and the fixed-effect model when there was no statistically significant heterogeneity (chi square P > 0.1). Trials of drug users were analysed separately. MAIN
RESULTS: Ten trials with 3985 participants met the inclusion criteria. There was no statistically significant difference between DOT and self administration of treatment for the number of people cured (RR 1.02, 95% CI 0.86 to 1.21, random-effects model; 1603 participants, 4 trials) or who were cured or completed treatment (RR 1.06, 95% CI 1.00 to 1.13; 1603 participants, 4 trials). Stratifying the location of the DOT by home or at a clinic suggests a possible small effect with home-based DOT (RR 1.10, 95% CI 1.02 to 1.18; 1365 participants, 3 trials). Two small trials of tuberculosis prophylaxis in intravenous drugs users found no statistically significant difference between DOT and self administration (199 participants, 1 trial), or a choice of location for DOT for completion of treatment (108 participants, 1 trial). AUTHORS'
CONCLUSIONS: The results of randomized controlled trials conducted in low-, middle-, and high-income countries provide no assurance that directly observed therapy compared with self-administered treatment has any quantitatively important effect on cure or treatment completion in people receiving treatment for tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16625579     DOI: 10.1002/14651858.CD003343.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  33 in total

Review 1.  Extending HIV care in resource-limited settings.

Authors:  Kara Wools-Kaloustian; Sylvester Kimaiyo
Journal:  Curr HIV/AIDS Rep       Date:  2006-11       Impact factor: 5.071

2.  Promoting adherence to treatment for tuberculosis: the importance of direct observation.

Authors:  Thomas R Frieden; John A Sbarbaro
Journal:  Bull World Health Organ       Date:  2007-05       Impact factor: 9.408

3.  Promoting adherence to tuberculosis treatment.

Authors:  Paul Garner; Helen Smith; Salla Munro; Jimmy Volmink
Journal:  Bull World Health Organ       Date:  2007-05       Impact factor: 9.408

4.  Bridging the gaps among research, policy and practice in ten low- and middle-income countries: development and testing of a questionnaire for researchers.

Authors:  David Cameron; John N Lavis; G Emmanuel Guindon; Tasleem Akhtar; Francisco Becerra Posada; Godwin D Ndossi; Boungnong Boupha
Journal:  Health Res Policy Syst       Date:  2010-01-29

5.  The Use of Research Evidence in Two International Organizations' Recommendations about Health Systems.

Authors:  Steven J Hoffman; John N Lavis; Sara Bennett
Journal:  Healthc Policy       Date:  2009-08

6.  Bridging the gaps between research, policy and practice in low- and middle-income countries: a survey of health care providers.

Authors:  G Emmanuel Guindon; John N Lavis; Francisco Becerra-Posada; Hossein Malek-Afzali; Guang Shi; C Ashok K Yesudian; Steven J Hoffman
Journal:  CMAJ       Date:  2010-05-03       Impact factor: 8.262

7.  Drug-resistant tuberculosis in Shanghai, China, 2000-2006: prevalence, trends and risk factors.

Authors:  X Shen; K DeRiemer; Z-An Yuan; M Shen; Z Xia; X Gui; L Wang; Q Gao; J Mei
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

Review 8.  Tuberculosis and illicit drug use: review and update.

Authors:  Robert G Deiss; Timothy C Rodwell; Richard S Garfein
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

9.  Tuberculosis in London: the importance of homelessness, problem drug use and prison.

Authors:  A Story; S Murad; W Roberts; M Verheyen; A C Hayward
Journal:  Thorax       Date:  2007-02-08       Impact factor: 9.139

10.  A qualitative examination of the indirect effects of modified directly observed therapy on health behaviors other than adherence.

Authors:  Andrea Bradley-Ewing; Domonique Thomson; Megan Pinkston; Kathy J Goggin
Journal:  AIDS Patient Care STDS       Date:  2008-08       Impact factor: 5.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.